Correlation Engine 2.0
Clear Search sequence regions

  • ABCB11 (1)
  • adult (1)
  • ALDH2 (1)
  • australia (1)
  • CDC45L (1)
  • cohort (1)
  • CYP4F2 (1)
  • diarrhea (1)
  • female (1)
  • free (3)
  • GSTM5 (1)
  • HNI (6)
  • humans (1)
  • irinotecan (10)
  • liver (1)
  • MTHFR (2)
  • neutropenia (1)
  • PARP1 (1)
  • patients (4)
  • phase (2)
  • rs2074900 (1)
  • SLC22A2 (2)
  • XRCC1 (1)
  • Sizes of these terms reflect their relevance to your search.

    Irinotecan (IR) displays significant PK/PD variability. This study evaluated functional hepatic imaging (HNI) and extensive pharmacogenomics (PGs) to explore associations with IR PK and PD (toxicity and response). Eligible patients (pts) suitable for Irinotecan-based therapy. At baseline: (i) PGs: blood analyzed by the Affymetrix-DMET™-Plus-Array (1936 variants: 1931 single nucleotide polymorphisms [SNPs] and 5 copy number variants in 225 genes, including 47 phase I, 80 phase II enzymes, and membrane transporters) and Sanger sequencing (variants in HNF1A, Topo-1, XRCC1, PARP1, TDP, CDC45L, NKFB1, and MTHFR), (ii) HNI: pts given IV 250 MBq-99mTc-IDA, data derived for hepatic extraction/excretion parameters (CLHNI, T1/2-HNI, 1hRET, HEF, Td1/2). In cycle 1, blood was taken for IR analysis and PK parameters were derived by non-compartmental methods. Associations were evaluated between HNI and PGs, with IR PK, toxicity, objective response rate (ORR) and progression-free survival (PFS). N = 31 pts. The two most significant associations between PK and PD with gene variants or HNI parameters (P < 0.05) included: (1) PK: SN38-Metabolic Ratio with CLHNI, 1hRET, (2) Grade 3+ diarrhea with SLC22A2 (rs 316019), GSTM5 (rs 1296954), (3) Grade 3+ neutropenia with CLHNI, 1hRET, SLC22A2 (rs 316019), CYP4F2 (rs2074900) (4) ORR with ALDH2 (rs 886205), MTHFR (rs 1801133). (5) PFS with T1/2-HNI, XDH (rs 207440), and ABCB11 (rs 4148777). Exploratory associations were observed between Irinotecan PK/PD with hepatic functional imaging and extensive pharmacogenomics. Further work is required to confirm and validate these findings in a larger cohort of patients. ACTRN12610000897066, Date registered: 21/10/2010.


    Michael Michael, Winston Liauw, Sue-Anne McLachlan, Emma Link, Annetta Matera, Michael Thompson, Michael Jefford, Rod J Hicks, Carleen Cullinane, Athena Hatzimihalis, Ian G Campbell, Simone Rowley, Phillip J Beale, Christos S Karapetis, Timothy Price, Mathew E Burge. Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. Cancer chemotherapy and pharmacology. 2021 Jul;88(1):39-52

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33755789

    View Full Text